Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2006 Sep;44(3):221-8.
doi: 10.3347/kjp.2006.44.3.221.

Safety and tolerability of elubaquine (bulaquine, CDRI 80/53) for treatment of Plasmidium vivax malaria in Thailand

Srivicha Krudsood  1 , Polrat Wilairatana, Noppadon Tangpukdee, Kobsiri Chalermrut, Siripun Srivilairit, Vipa Thanachartwet, Sant Muangnoicharoen, Natthanej Luplertlop, Gary M Brittenham, Sornchai Looareesuwan
Affiliations
Randomized Controlled Trial

Safety and tolerability of elubaquine (bulaquine, CDRI 80/53) for treatment of Plasmidium vivax malaria in Thailand

Srivicha Krudsood et al. Korean J Parasitol. 2006 Sep.

Abstract

We conducted a study to compare the safety and tolerability of anti-relapse drugs elubaquine and primaquine against Plasmodium vivax malaria. After standard therapy with chloroquine, 30 mg/kg given over 3 days, 141 patients with P. vivax infection were randomized to receive primaquine or elubaquine. The 2 treatment regimens were primaquine 30 mg once daily for 7 days (group A, n = 71), and elubaquine 25 mg once daily for 7 days (group B, n = 70). All patients cleared parasitemia within 7 days after chloroquine treatment. Among patients treated with primaquine, one patient relapsed on day 26; no relapse occurred with elubaquine treatement. Both drugs were well tolerated. Adverse effects occurred only in patients with G6PD deficiency who were treated with primaquine (group A, n = 4), whose mean hematocrit fell significantly on days 7, 8 and 9 (P = 0.015, 0.027, and 0.048, respectively). No significant change in hematocrit was observed in patients with G6PD deficiency who were treated with elubaquine (group B, n = 3) or in patients with normal G6PD. In conclusion, elubaquine, as anti-relapse therapy for P. vivax malaria, was as safe and well tolerated as primaquine and did not cause clinically significant hemolysis.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Reduction in the pertentage of malaria parasites during treatment.
Fig. 2
Fig. 2
Hematocrit in patients with normal levels of G6PD during the study period.
Fig. 3
Fig. 3
Hematocrit in patients with deficient levels of G6PD during the study period.
See this image and copyright information in PMC

References

    1. Adak T, Valecha N, Sharma VP. Plasmodium vivax polymorphism in a clinical drug trial. Clin Diagn Lab Immunol. 2001;8:891–894. - PMC - PubMed
    1. Anklesaria PS, Ashar VJ, Kshirsagar NA, Gupta KC. Comparison of the effect of compound CDRI 80/53 [N1-(3 acetyl-4-5-dihydro-2 furanyl)-N4-(6-methoxy-8-quinolinyl)1,4-pentanediamine] with primaquine on human erythrocytes in vitro. In: Kumar S, Sen AK, Dutta GP, Sharma RN, editors. Tropical Diseases: Molecular Biology and Control Strategies. New Delhi, India: Publication and Information Directorate, Council of Scientific and Industrial Research; 1994.
    1. Baird JK. Chloroquine resistance in Plasmodium vivax. Antimicrob Agents Chemother. 2004;48:4075–4083. - PMC - PubMed
    1. Baird JK, Hoffman SL. Primaquine therapy for malaria. Clin Infect Dis. 2004;39:1336–1345. - PubMed
    1. Baird JK, Leksana B, Masbar S, Fryauff DJ, Sutanihardja MA, Suradi, Wignall FS, Hoffman SL. Diagnosis of resistance to chloroquine by Plasmodium vivax: timing of recurrence and whole blood chloroquine levels. Am J Trop Med Hyg. 1997;56:621–626. - PubMed

Publication types

LinkOut - more resources